First, our findings cannot simply be extended to all bladder cancer cells, despite our investigation of the effects of pharmacological ATR inhibition in three bladder cancer cell lines that represent bladder cancer heterogeneity. This evidence concerns the gene ATR and urinary bladder carcinoma.